These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12412159

  • 1. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
    Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP.
    Cancer; 2002 Nov 15; 95(10):2068-75. PubMed ID: 12412159
    [Abstract] [Full Text] [Related]

  • 2. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A.
    Eur J Surg Oncol; 2006 Dec 15; 32(10):1097-100. PubMed ID: 16650962
    [Abstract] [Full Text] [Related]

  • 3. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
    Foulkes WD, Wong N, Brunet JS, Bégin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2465-9. PubMed ID: 9815648
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benítez J.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [Abstract] [Full Text] [Related]

  • 5. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD.
    Cancer; 2003 Feb 01; 97(3):527-36. PubMed ID: 12548593
    [Abstract] [Full Text] [Related]

  • 6. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 01; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 7. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
    Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI.
    Cancer Res; 2002 Mar 01; 62(5):1481-8. PubMed ID: 11888924
    [Abstract] [Full Text] [Related]

  • 8. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R, Apple SK, He J, Gornbein JA, Chang HR.
    Breast J; 2005 Mar 01; 11(6):433-9. PubMed ID: 16297088
    [Abstract] [Full Text] [Related]

  • 9. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G.
    Clin Cancer Res; 2001 Jul 01; 7(7):1937-45. PubMed ID: 11448907
    [Abstract] [Full Text] [Related]

  • 10. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K.
    Cancer Res; 1998 May 01; 58(9):1839-42. PubMed ID: 9581822
    [Abstract] [Full Text] [Related]

  • 11. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM.
    Breast Cancer Res Treat; 2008 Jul 01; 110(1):99-109. PubMed ID: 17851763
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA.
    N Engl J Med; 2007 Jul 12; 357(2):115-23. PubMed ID: 17625123
    [Abstract] [Full Text] [Related]

  • 13. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R, Sagi S, Lahad EL, Auslander R, Beller U.
    Gynecol Oncol; 2004 Feb 12; 92(2):521-4. PubMed ID: 14766242
    [Abstract] [Full Text] [Related]

  • 14. Histopathological criteria and selection algorithms for BRCA1 genetic testing.
    Gadzicki D, Schubert A, Fischer C, Milde S, Lehmann U, Steinemann D, Lück HJ, Kreipe H, Schlegelberger B.
    Cancer Genet Cytogenet; 2009 Mar 12; 189(2):105-11. PubMed ID: 19215791
    [Abstract] [Full Text] [Related]

  • 15. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.
    Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Bégin LR, Brunet JS, Narod SA.
    Cancer; 2003 Oct 15; 98(8):1569-77. PubMed ID: 14534871
    [Abstract] [Full Text] [Related]

  • 16. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B.
    Gynecol Oncol; 2000 Oct 15; 79(1):74-8. PubMed ID: 11006035
    [Abstract] [Full Text] [Related]

  • 17. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D.
    Cancer Res; 2003 Jan 15; 63(2):342-7. PubMed ID: 12543786
    [Abstract] [Full Text] [Related]

  • 18. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N.
    Am J Hematol; 2005 Mar 15; 78(3):203-6. PubMed ID: 15726604
    [Abstract] [Full Text] [Related]

  • 19. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005 Mar 15; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 20. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
    Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ.
    Cancer; 1998 Dec 01; 83(11):2335-45. PubMed ID: 9840533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.